TNFRSF17 and plasma cell myeloma: The use of anti-BCMA in the management of multiple myeloma has been incorporated into the current guidelines, which entail the use of this treatment, combined with the nonresponsive use of triple therapy beforehand, for relapsed/refractory multiple myeloma [13].